Cytokinetics, Incorporated Insider Trading

CYTK

Last 12 months

Insiders sold $52.1M and bought nothing on the open market.

91% of the selling was scheduled in advance under 10b5-1 plans. President & CEO Robert I Blum sold $2.27M on Mar 17, 7.8% of their stake, outside a plan. The last open-market buy by an executive or director was in Nov 2019.

Net open-market

−$52.1M

0 buys · 77 sales

Under a 10b5-1 plan

91%

of the value sold

Insiders who bought / sold

0 / 10

executives and directors

Last open-market buy

Nov 2019

Nov 19, 2019

Get an email when CYTK's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Nov 3	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$62.93	220K	2.2%	Form 4
Nov 2	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$62.81	471K	2.6%	Form 4
Oct 20	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$64.01	224K	2.2%	Form 4
Oct 12	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$62.88	472K	2.6%	Form 4
Oct 6	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$61.38	215K	2.2%	Form 4
Sep 28	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$65.46	491K	2.6%	Form 4
Sep 22	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$68.29	239K	2.2%	Form 4
Sep 15	Robert E Landry Director	Sold10b5-1 plan	1,000	$72.13	72K	11%	Form 4
Sep 14 – 15	Robert I Blum President & CEO	Sold10b5-1 plan 2 parts	105,426	$69.62 average	$7.34M	27%	Form 4
Sep 11	Robert E Landry Director	Sold10b5-1 plan	1,000	$74.66	75K	9.8%	Form 4
Sep 8	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$75.46	264K	2.2%	Form 4
Sep 1	B Lynne Parshall Director	Sold10b5-1 plan	5,000	$71.48	357K	32%	Form 4
Aug 31	Andrew Callos EVP, Chief Commercial Officer	Sold10b5-1 plan	10,000	$70.24	702K	15%	Form 4
Aug 31	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$70.24	527K	1.9%	Form 4
Aug 18	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$75.82	265K	2.2%	Form 4
Aug 10	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$76.76	576K	1.9%	Form 4
Jul 30	Andrew Callos EVP, Chief Commercial Officer	Sold10b5-1 plan	14,000	$79.88	$1.12M	19%	Form 4
Jul 27	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$80.87	607K	1.9%	Form 4
Jul 21	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$80.59	282K	2.2%	Form 4
Jul 13	Robert I Blum President & CEO	Sold10b5-1 plan 2 parts	7,500	$82.02 average	615K	1.9%	Form 4
Jul 7	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$86.62	303K	2.2%	Form 4
Jul 1	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$84.92	637K	1.9%	Form 4
Jul 1	Andrew Callos EVP, Chief Commercial Officer	Sold10b5-1 plan	15,000	$85.80	$1.29M	20%	Form 4
Jul 1	Sung Lee EVP, Chief Financial Officer	Sold10b5-1 plan	1,112	$87.79	98K	1.7%	Form 4
Jun 29	Sung Lee EVP, Chief Financial Officer	Sold10b5-1 plan	3,134	$85.00	266K	4.7%	Form 4
Jun 24	Sung Lee EVP, Chief Financial Officer	Sold10b5-1 plan	38,730	$82.30	$3.19M	38%	Form 4
Jun 23	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$79.51	278K	2.2%	Form 4
Jun 15	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$70.46	528K	1.9%	Form 4
Jun 9	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$67.98	238K	2.2%	Form 4
Jun 1	Edward M. Md Kaye Director	Sold10b5-1 plan	2,933	$76.09	223K	22%	Form 4
Jun 1	Andrew Callos EVP, Chief Commercial Officer	Sold10b5-1 plan	15,000	$74.08	$1.11M	20%	Form 4
Jun 1	B Lynne Parshall Director	Sold10b5-1 plan	5,000	$74.08	370K	24%	Form 4
May 27	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$77.21	579K	1.9%	Form 4
May 19	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$75.69	265K	2.2%	Form 4
May 14	Robert I Blum President & CEO	Sold10b5-1 plan	7,500	$77.92	584K	1.8%	Form 4
May 5	Fady Ibraham Malik EVP Research & Development	Sold10b5-1 plan	3,500	$77.37	271K	2.2%	Form 4
May 5	Wendell Wierenga Director	Sold10b5-1 plan	4,032	$75.00	302K	11%	Form 4
May 5	Sung Lee EVP, Chief Financial Officer	Sold10b5-1 plan	23,906	$76.87	$1.84M	27%	Form 4
May 5	John T Henderson Director	Sold10b5-1 plan	20,000	$75.97	$1.52M	21%	Form 4
May 5	Andrew Callos EVP, Chief Commercial Officer	Sold10b5-1 plan	11,333	$77.25	875K	16%	Form 4

Nov 310b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $62.93
220K
2.2% of stake
Nov 210b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $62.81
471K
2.6% of stake
Oct 2010b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $64.01
224K
2.2% of stake
Oct 1210b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $62.88
472K
2.6% of stake
Oct 610b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $61.38
215K
2.2% of stake
Sep 2810b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $65.46
491K
2.6% of stake
Sep 2210b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $68.29
239K
2.2% of stake
Sep 1510b5-1 plan
Robert E Landry
Director · sold 1,000 at $72.13
72K
11% of stake
Sep 14 – 1510b5-1 plan
Robert I Blum
President & CEO · sold 105,426 at avg $69.62
$7.34M
27% of stake
Sep 1110b5-1 plan
Robert E Landry
Director · sold 1,000 at $74.66
75K
9.8% of stake
Sep 810b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $75.46
264K
2.2% of stake
Sep 110b5-1 plan
B Lynne Parshall
Director · sold 5,000 at $71.48
357K
32% of stake
Aug 3110b5-1 plan
Andrew Callos
EVP, Chief Commercial Officer · sold 10,000 at $70.24
702K
15% of stake
Aug 3110b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $70.24
527K
1.9% of stake
Aug 1810b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $75.82
265K
2.2% of stake
Aug 1010b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $76.76
576K
1.9% of stake
Jul 3010b5-1 plan
Andrew Callos
EVP, Chief Commercial Officer · sold 14,000 at $79.88
$1.12M
19% of stake
Jul 2710b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $80.87
607K
1.9% of stake
Jul 2110b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $80.59
282K
2.2% of stake
Jul 1310b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at avg $82.02
615K
1.9% of stake
Jul 710b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $86.62
303K
2.2% of stake
Jul 110b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $84.92
637K
1.9% of stake
Jul 110b5-1 plan
Andrew Callos
EVP, Chief Commercial Officer · sold 15,000 at $85.80
$1.29M
20% of stake
Jul 110b5-1 plan
Sung Lee
EVP, Chief Financial Officer · sold 1,112 at $87.79
98K
1.7% of stake
Jun 2910b5-1 plan
Sung Lee
EVP, Chief Financial Officer · sold 3,134 at $85.00
266K
4.7% of stake
Jun 2410b5-1 plan
Sung Lee
EVP, Chief Financial Officer · sold 38,730 at $82.30
$3.19M
38% of stake
Jun 2310b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $79.51
278K
2.2% of stake
Jun 1510b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $70.46
528K
1.9% of stake
Jun 910b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $67.98
238K
2.2% of stake
Jun 110b5-1 plan
Edward M. Md Kaye
Director · sold 2,933 at $76.09
223K
22% of stake
Jun 110b5-1 plan
Andrew Callos
EVP, Chief Commercial Officer · sold 15,000 at $74.08
$1.11M
20% of stake
Jun 110b5-1 plan
B Lynne Parshall
Director · sold 5,000 at $74.08
370K
24% of stake
May 2710b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $77.21
579K
1.9% of stake
May 1910b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $75.69
265K
2.2% of stake
May 1410b5-1 plan
Robert I Blum
President & CEO · sold 7,500 at $77.92
584K
1.8% of stake
May 510b5-1 plan
Fady Ibraham Malik
EVP Research & Development · sold 3,500 at $77.37
271K
2.2% of stake
May 510b5-1 plan
Wendell Wierenga
Director · sold 4,032 at $75.00
302K
11% of stake
May 510b5-1 plan
Sung Lee
EVP, Chief Financial Officer · sold 23,906 at $76.87
$1.84M
27% of stake
May 510b5-1 plan
John T Henderson
Director · sold 20,000 at $75.97
$1.52M
21% of stake
May 510b5-1 plan
Andrew Callos
EVP, Chief Commercial Officer · sold 11,333 at $77.25
875K
16% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch CYTK, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with CYTK

CompareIntrinsic value

DERMJourney Medical Corp

$4.73+1.94%25

FBIOFortress Biotech Inc.

$1.97+1.55%59

ABCLAbCellera Biologics Inc.

$12.28+0.82%10

RMTIRockwell Medical, Inc.

$8.05-0.49%37

ENTAEnanta Pharmaceuticals Inc.

$10.65+2.70%25

VRDNViridian Therapeutics Inc.

$29.06+15.53%40

XLOXilio Therapeutics, Inc.

$8.71+0.35%40

BCYCBicycle Therapeutics PLC

$3.72+1.36%40

Held by ETFs

CYTK is in 114 US ETFs. The largest of them, with CYTK's weight in each:

Spot a number that looks wrong? Check it in CYTK's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing CYTK

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.